Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters.
about
Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression.Excretion of cyclosporine and its metabolites in human bile.Allograft and xenograft acceptance under FK-506 and other immunosuppressant treatment.Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group.Species differences in sensitivity of T lymphocytes to immunosuppressive effects of FK 506.Toxoplasmosis in cardiac transplantationIn vitro assessment of FK 506 immunosuppressive activity in transplant patients.Cyclosporin A pharmacokinetics in liver transplant recipients in relation to biliary T-tube clamping and liver dysfunction.Pharmacokinetics of cyclosporin: influence of rate of constant intravenous infusion in renal transplant patientsThymic and lymphoid changes and serum immunoglobulin abnormalities in mice receiving cyclosporine.Morphometric and ultrastructural analysis of the effect of bromocriptine and cyclosporine on the vasospastic femoral artery of rats.Sirolimus enhances cyclosporine a-induced cytotoxicity in human renal glomerular mesangial cellsEffect of a stable analogue of prostacyclin on cyclosporine A-induced nephrotoxicity: morphological qualitative and quantitative studies.The influence of liver dysfunction on cyclosporine pharmacokinetics--a comparison between 70 per cent hepatectomy and complete bile duct ligation in dogs.A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation.Cyclosporin metabolism by the gastrointestinal mucosa.Cyclosporin metabolism by human gastrointestinal mucosal microsomes.
P2860
Q33993525-CE92910B-6C6D-4B4C-89E4-BE4910E8B88BQ33993557-919B9F5A-C262-4B33-B271-4E8AE46D38F5Q34178489-D207E2F7-020B-4B38-B03A-43C5E130278FQ34275380-A289AE67-6C22-4532-9A96-7DFF02ADE0F3Q34280890-B320FD1A-889F-4649-9145-683815A79203Q34285304-6CF816A4-6850-451F-AC6F-0DCA0C438111Q34312221-9B8927E3-928B-4D32-8388-A3740AC40419Q34392206-FECB57AD-D589-4F21-914D-A12DF7526488Q34417056-0AFAAAF9-B4AB-4F25-AD2C-FEC45D9E5290Q35856501-48FE64B9-72C2-4031-80A8-9A389198AF47Q40104978-808374CC-5D8F-445C-8444-9460B39B7BBEQ40793003-6D4DAF2B-1F4E-4369-B360-9A5F1AC4E169Q41170395-22593C72-2C8B-4858-B21A-54E4C2863E95Q41712318-D7A27C45-A226-4D10-AA03-CC78398D77FDQ41786958-57BAF833-11C2-4037-89A1-F03AAF72E2BCQ42100974-03BE8865-0D6F-44CF-B925-E73D4AF3F82FQ43224335-C094AD4D-FD11-4A14-842A-36438441A889
P2860
Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年学术文章
@wuu
1985年学术文章
@zh-cn
1985年学术文章
@zh-hans
1985年学术文章
@zh-my
1985年学术文章
@zh-sg
1985年學術文章
@yue
1985年學術文章
@zh
1985年學術文章
@zh-hant
name
Individualization of cyclospor ...... nd pharmacodynamic parameters.
@en
Individualization of cyclospor ...... nd pharmacodynamic parameters.
@nl
type
label
Individualization of cyclospor ...... nd pharmacodynamic parameters.
@en
Individualization of cyclospor ...... nd pharmacodynamic parameters.
@nl
prefLabel
Individualization of cyclospor ...... nd pharmacodynamic parameters.
@en
Individualization of cyclospor ...... nd pharmacodynamic parameters.
@nl
P1433
P1476
Individualization of cyclospor ...... nd pharmacodynamic parameters.
@en
P2093
P304
P577
1985-11-01T00:00:00Z